BIOmarkers of Dyspnea IN Emergency Room (BIODINER)

B·R·A·H·M·S

Status: Completed

Conditions: Pulmonary Embolism; Severe Dyspnea; Acute Heart Failure; CAPD; AE COPD

Treatments: Other: Prognostic value of Biomarkers

Study type: Observational

Funder types: Industry

Identifiers

NCT01227317

BIODINER BRAHMS France

Details and patient eligibility

About

The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine vasopressin), Pro endothelin to stratify the risk in severe dyspnea.

Full description

In emergency department shortness of breath (SOB)is a common symptom and its cause is not easy to be identified. The risk stratifying remains a challenge, Prognostic value of biomarkers might be helpful.

Enrollment: 444 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• tachypnea > 25 /min or Pa02 < 70 mmHg or SpO2 < 93%
• diagnosis suspected: CAP, PE,EACOPD, AHF

Exclusion criteria

• other cause of dyspnea,
• unreachable on Day 30

Trial design

444 participants in 1 patient group

Acute dyspnea in ED

Description:

Acute severe shortness of breath (SOB) in emergency Department (ED) with suspicion of acute heart failure (AHF) or Pulmonary Embolism (PE)or Community-acquired pneumonia (CAP) or acute Exacerbation of chronic obstructive pulmonary disease (AE COPD)

Treatment:

Other: Prognostic value of Biomarkers